Awareness: The PCCN-Toronto and Side by Side Prostate Cancer Support Groups Newsletter. In this Issue: Join us on Father’s day morning for our annual “Do it for dads” Walk Run! Jan. Awareness Night: Dr. Raj Satkunasivam: The future of PSA-based prostate cancer screening: screening smarter and individualized risk assessment We’d like to welcome a new sponsor – JANSSEN PHARMACEUTICALS PCCN-Toronto Volunteers Participate in PCC’s “SHOP FOR A CAUSE” with Tommy Bahama Stores A new sponsor for our 2017 newsletter – KELLER WILLIAMS Neighbourhood Realty March Awareness Night: Dr. Joseph LaBossiere: Andrology: focuses on diseases & conditions specific to men! Ask the […]
Medical journalist Anna Magee reveals the eight proven ways to lower your risk. Read the article here.
Leading American and British cancer researchers are urging that all men with advanced prostate cancer strongly consider being tested for inherited gene mutations — both to help steer their treatment and to alert family members who themselves might be at increased risk for a range of cancers. Read the article here.
A new study offers important information to men who are facing difficult decisions about how to treat prostate cancer in its early stages, or whether to treat it at all. Researchers followed patients for 10 years and found no difference in death rates between men who were picked at random to have surgery or radiation, or to rely on “active monitoring” of the cancer, with treatment only if it progressed. Read the article here.
Loyola Medicine is the first center in the Midwest to offer the first effective PET/CT scan for prostate cancer patients. The scan can detect the location and extent of cancer that has recurred after initial treatment and spread to other parts of the body. Prostate PET/CT scans can detect cancer earlier than either CT scans alone or MRI scans. Read the article here.
Scientists at Cedars-Sinai Medical Center have developed a new way to identify which prostate cancer patients are likely to develop aggressive types of the disease even if their tumors at first appear to be lower risk. Read the article here.
A small Canadian company has waded into a U.S. drug price controversy by offering to make an expensive prostate cancer drug for a fraction of the price. Right now Xtandi costs U.S. patients as much as $129,000 US a year, or about $90 per pill. St. Catharines, Ont.-based Biolyse Pharma says it can make the drug for $3 a pill, or $4,400 per year, but has so far been unable to get U.S. health authorities to override the existing patent. Read the article here.
Scientists with Deakin’s School of Medicine have found that, when coupled with the milk protein lactoferrin, the chemotherapy drug Doxorubicin (Dox) can be delivered directly into the nucleus of prostate cancer cells and will kill them cells as well as drug resistant cancer stem cells, without any side-effects. Read the article here.
A man’s race/ethnicity might influence decision-making regarding opting for active treatment as well as undergoing serial biopsies during active surveillance, according to a recent study. Read the article here.
Elevated cholesterol and triglycerides increase prostate cancer recurrence risk, according to research. Read the article here.